NEW YORK, April 16, 2015 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research announced its "Kick in to Stop Sarcoidosis" ("K.I.S.S.") New York Fundraiser on Thursday, April 16th, 2015 with the support of EnGeneIC, Ltd., who is propagating a unique interest in the Foundation. The event is being held at SoHo's Rotella Gallery. It marks the first time that the Foundation for Sarcoidosis Research (FSR) is bringing this fundraiser to New York, following successful past events in Chicago and other cities.
FSR, the nation's leading nonprofit organization dedicated to improving care for Sarcoidosis patients, hosts this annual event to raise funds for research initiatives aimed at better understanding the causes of Sarcoidosis and advancing the potential for a cure. Sarcoidosis is a potentially fatal inflammatory disease that can appear in almost any organ in the body. Although the lungs are affected in more than 90% of patients, the disease often attacks the heart, eyes, central nervous system, liver and kidneys. There is currently no known cause, very few treatments available, and no cure.
"Responsible corporate citizenship is fundamental to our mission at EnGeneIC. We are proud to play a key role in the first-ever K.I.S.S. fundraiser in New York. EnGeneIC as a company is focused on developing breakthrough therapies for patients living with cancer, but we recognize the importance of raising awareness for rare diseases as well," said Anjan Chatterji, EVP Corporate Development at EnGeneIC. "Having recently been named FSR Board President, this is a cause that is extremely important to me, and I am grateful to the EnGeneIC management team and Board of Directors for enabling the company to take its support of FSR to the next level through our involvement in this event."
About the Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research is the nation's leading nonprofit organization dedicated to finding a cure for this disease and to improving care for Sarcoidosis patients. Since its establishment in 2000, FSR has funded numerous domestic and international research efforts and has worked diligently to provide resources to thousands. FSR provides funding and collaborations for research and initiatives which focus on the understanding of Sarcoidosis, addresses the causes of the disease, counters the suffering of patients, and advances the potential for a cure. Through venture philanthropy, general fundraising, and collaborations with the pharmaceutical industry, biotech companies, medical institutes and professionals, academic institutes, researchers, and patients from across the globe, FSR is producing game-changing initiatives toward a cure. For more information about FSR, please visit: www.stopsarcoidosis.org.
About EnGeneIC, Ltd.
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutic and other therapeutic molecules. The company's lead technology platform, EDV™ utilizes antibody-targeted, bacterially derived, non-living "nanocells" to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells. In doing so, EDV™ nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers. EnGeneIC is currently preparing an IND for FDA submission, with plans to launch a Phase1/2a clinical trial in recurrent glioblastoma patients in early 2015. Trials are also in planning stages for non-small cell lung cancer.
The event, showcased in a world-renowned gallery, will introduce FSR's innovative approach to accelerating research, and will build on its strong network of stakeholders. For additional information, please contact katie@stopsarcoidosis.org.